Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
暂无分享,去创建一个
O. Kirk | R. Weber | C. Sabin | A. Phillips | P. Reiss | J. Lundgren | W. El-Sadr | M. Law | A. Monforte | S. De Wit | C. Pradier | R. Thiébaut | N. Friis-Møller | L. Morfeldt | S. Mateu | N. Friis‐Møller
[1] O. Kirk,et al. Modelling the 3‐year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) study , 2003, HIV medicine.
[2] O. Kirk,et al. Lipid profiles on therapy with PI: The D:A:D (Data collection on adverse events of anti-HIV drugs) study , 2002 .
[3] S. Sidney,et al. Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV‐1 Infection? , 2002, Journal of acquired immune deficiency syndromes.
[4] C. Moore,et al. Rates of combination antiretroviral treatment change in Australia, 1997–2000 , 2002 .
[5] M. Moroni,et al. Body Habitus Changes and Metabolic Alterations in Protease Inhibitor‐Naive HIV‐1‐Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors , 2002, Journal of acquired immune deficiency syndromes.
[6] O. Kirk,et al. Distinguishable Lipid Profiles between PI and NNRTI Therapy may carry different risk of cariovascular disease (CVD) , 2002 .
[7] Bg Gazzard and. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.
[8] B Clotet,et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile , 2001, AIDS.
[9] M. Dubé,et al. Elevated blood pressure in subjects with lipodystrophy , 2001, AIDS.
[10] P. Reiss,et al. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. , 2001, Nederlands tijdschrift voor geneeskunde.
[11] Nina Singh,et al. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy , 2001, International journal of STD & AIDS.
[12] P. Cadrobbi,et al. Indinavir and systemic hypertension. , 2001, AIDS.
[13] A. Astrup,et al. Obesity : Preventing and managing the global epidemic , 2000 .
[14] R. Weber,et al. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. , 2000, AIDS.
[15] J. Mallolas,et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] D. Cooper,et al. Adverse effects of antiretroviral therapy , 2000, The Lancet.
[17] P. Francioli,et al. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. , 2000, Schweizerische medizinische Wochenschrift.
[18] S. Hammer,et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. , 2000, Archives of internal medicine.
[19] H Jacqmin-Gadda,et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment , 2000, AIDS.
[20] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[21] H. Jacqmin-Gadda,et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). , 2000, Journal of acquired immune deficiency syndromes.
[22] M A Fischl,et al. Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .
[23] J. Leonard,et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.
[24] O. Rouvière,et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study , 2000, AIDS.
[25] N. Clumeck,et al. Cerebral Toxoplasmosis over the last 10 years in a 2394 patient cohort in Brussels , 2000 .
[26] B. Gazzard,et al. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. , 2000, Journal of acquired immune deficiency syndromes.
[27] C. Grunfeld,et al. Fat distribution and metabolic changes in patients with HIV infection. , 1999, AIDS.
[28] K. Tashima,et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.
[29] L. Bricker,et al. Myocardial Infarction in HIV-Infected Men Receiving Protease Inhibitors , 1999, Annals of Internal Medicine.
[30] L. Poston,et al. British Hypertension Society guidelines for hypertension management 1999: summary , 1999, BMJ.
[31] S M Marcovina,et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.
[32] H. Schmidt,et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. , 1999, AIDS.
[33] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[34] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[35] D. Grafnetter,et al. Quality assessment of total cholesterol measurements in the WHO MONICA Project , 1999 .
[36] M. Karmochkine,et al. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. , 1998, AIDS.
[37] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[38] C. Pradier,et al. Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T‐cell count? , 1998, AIDS.
[39] F. Goebel,et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.
[40] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[41] D. Vittecoq,et al. Vascular complications associated with use of HIV protease inhibitors , 1998, The Lancet.
[42] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.
[43] K. Henry,et al. Severe premature coronary artery disease with protease inhibitors , 1998, The Lancet.
[44] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[45] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[46] J. Nielsen,et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[47] C. Packard,et al. Point: status of lipid and lipoprotein standardization. , 1997, Clinical chemistry.
[48] C. Sergeant,et al. Plasma lipids in HIV‐infected patients: a prospective study in 95 patients , 1994, European journal of clinical investigation.
[49] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[50] John W. Ward,et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[51] J. Wang,et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1989, The American journal of medicine.
[52] J. Ordovás,et al. Postprandial plasma lipoprotein changes in human subjects of different ages. , 1988, Journal of lipid research.
[53] S. J. Smith,et al. Standardization of lipid, lipoprotein, and apolipoprotein measurements. , 1988, Clinical chemistry.
[54] HELEN B. HUBERT,et al. Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.
[55] A. Dyer,et al. Epidemiologic findings on the relationship of time of day and time since last meal to five clinical variables: serum cholesterol, hematocrit, systolic and diastolic blood pressure, and heart rate. , 1978, Preventive medicine.